TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00752115
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg, day1,8 and 15 in each cycle
Study: NCT01383096
Drug: OZ439 mesylate 800mg Prototype Solution Formula 2
Normalized name: benztropine mesylate 2 MG
DrugBank: Benzatropine (DB00245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OZ439 800 mg (as free base) as a prototype solution formulation 2
Study: NCT00752115
Drug: paclitaxel (taxol)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
Study: NCT00752115
Drug: carboplatin (palaplatin)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin; AUC=6 on day 1, every 28 days
Study: NCT03862040
Drug: Cefiderocol
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously, at a dosage determined based on renal function.
Study: NCT01835470
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03660488
Drug: Cefixime 400 milligram Oral Capsule [Suprax]
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days
Study: NCT04684524
Drug: Dupilumab SAR231893
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study: NCT01011907
Drug: varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
Study: NCT00894465
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG
Study: NCT00679744
Drug: Pyrimethamine
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrimethamine will be given PO once daily for 8 consecutive weeks.
Study: NCT01497574
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
Study: NCT01497574
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
Study: NCT02086526
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
Study: NCT04569032
Drug: brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
Study: NCT04569032
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg daily administered orally on Days 1-5 of each cycle
Study: NCT00909181
Drug: Oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo
Study: NCT03288870
Drug: BCD-100
Normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monoclonal antibody to PD-1 receptor
Study: NCT03288870
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy drug (taxane)
Study: NCT00404066
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)
Study: NCT00404066
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
Study: NCT00404066
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
Study: NCT00404066
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
Study: NCT00404066
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
Study: NCT00404066
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year
Study: NCT00127868
Drug: oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03794583
Drug: Inhaled treprostinil solution
Normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhaled treprostinil solution per dose and schedule specified in the arm
Study: NCT00408330
Drug: Azelaic Acid 15% Gel
Normalized name: AZELAIC ACID 15% GEL,TOP
DrugBank: Azelaic acid (DB00548)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15% gel, topically applied daily for six weeks
Study: NCT00610545
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
Study: NCT00610545
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
Study: NCT04216186
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine once daily
Study: NCT04216186
Drug: Coenzyme Q
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q once daily
Study: NCT02885948
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: used to block the effects of opioids, especially in overdose
Study: NCT00437385
Drug: TCAs, SSRIs, NARIs, SNRIs, Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
Study: NCT03312582
Drug: 1% local metformin gel
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
Study: NCT04094077
Drug: AGuIX
Normalized name: AGuIX
DrugBank: AGuIX (DB18189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
Study: NCT01849939
Drug: Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)
Normalized name: Cepacol Sore Throat from Post Nasal Drip
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05986292
Drug: LY3016859 ISA
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (IV)
Study: NCT05986292
Drug: LY3556050 ISA
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05986292
Drug: LY3526318 ISA
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05986292
Drug: LY3857210 ISA
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04926454
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously.~patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia
Study: NCT04417530
Drug: AU-011
Normalized name: Light-activated au-011
DrugBank: Belzupacap Sarotalocan (DB17317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AU-011 Via Suprachoroidal Administration
Study: NCT01165372
Drug: Artesunate or dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
Study: NCT05378646
Drug: Interferon gamma human recombinant (IFN-G)
Normalized name: interferon gamma, porcine recombinant
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study: NCT01423812
Drug: Twice-daily combination Darunavir and ritonavir
Normalized name: clindamycin
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects randomized 1:1 to remain on regimens containing combination Darunavir 600mg plus Ritonavir 100mg twice-daily
Study: NCT03764488
Drug: Tofersen
Normalized name: Tofersen
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02301910
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~* 55 to \<60 30 mg 6 ml~* 60 to \<70 35 mg 7 ml~* 70 to \<80 40 mg 8 ml
Study: NCT03711058
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV
Study: NCT03711058
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV
Study: NCT01423812
Drug: Once-daily combination Darunavir and ritonavir
Normalized name: clindamycin
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects randomized 1:1 to switch to from combination Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to the experimental combination Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
Study: NCT02845882
Drug: Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
Study: NCT02565927
Drug: Iodine-125 seeds
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: process intraluminal brachytherapy
Study: NCT03758989
Drug: Rituximab Prednisone
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Study: NCT03758989
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Study: NCT03758989
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Study: NCT00041080
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00041080
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00805662
Drug: oxytocin, placebo
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal oxytocin during intrauterine insemination
Study: NCT02811055
Drug: Administration of Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Aprepitant 80 mg once per day during 14 days
Study: NCT01084603
Drug: Oral Nicotine
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A new l mg oral nicotine product
Study: NCT01084603
Drug: NiQuitinTM Nicotine Lozenge
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A marketed 4 mg Nicotine lozenge
Study: NCT01084603
Drug: Nicorette® Nicotine Gum
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A marketed 4 mg Nicotine Gum
Study: NCT00207714
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
Study: NCT00207714
Drug: MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
Study: NCT00207714
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
Study: NCT02545010
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician.
Study: NCT04123795
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use
Study: NCT00812344
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets, orally, once daily for 3 days
Study: NCT00812344
Drug: ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
Study: NCT00939952
Drug: ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg IV once
Study: NCT01057901
Drug: Flibanserin
Normalized name: Flibanserin
DrugBank: Flibanserin (DB04908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flibanserin 100mg administered at bedtime for 24 weeks
Study: NCT01036061
Drug: GSK618334 Low Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GSK618334 low dose
Study: NCT01036061
Drug: GSK618334 High Dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK618334 High Dose
Study: NCT00999921
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
Study: NCT00999921
Drug: Evening Primrose Oil
Normalized name: Evening Primrose Oil
DrugBank: Evening primrose oil (DB11358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
Study: NCT00890188
Drug: THALIDOMIDE and UFUR
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
Study: NCT03328078
Drug: Emavusertib
Normalized name: Emavusertib
DrugBank: Emavusertib (DB18060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emavusertib will be provided as a tablet dosage form to be taken BID.
Study: NCT03328078
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.
Study: NCT00005036
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00005036
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00314249
Drug: Milnacipran 100mg
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran 100mg per day (50mg BID \[twice a day\])
Study: NCT00184626
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00184626
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00184626
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00004699
Drug: insulin-like growth factor I
Normalized name: Insulin-like growth factor I
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02129660
Drug: Dose 1 of glycopyrronium, 2.5% QD
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 of glycopyrronium Topical Wipes
Study: NCT02129660
Drug: Dose 2 of glycopyrronium, 3.75% QD
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2 of glycopyrronium Topical Wipes
Study: NCT02503345
Drug: ALLN-177 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
Study: NCT04275661
Drug: levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
Study: NCT04275661
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg /kg ketamine.injected into fascial plane deep to erector spinae muscle
Study: NCT04275661
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mg/kg Magnesium Sulfate .injected into fascial plane deep to erector spinae muscle
Study: NCT02503345
Drug: ALLN-177 high dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
Study: NCT02360397
Drug: ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine 1000 mg tablet twice daily for 30 days
Study: NCT03031405
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00610584
Drug: cetirizine dihydrochloride (rescue medication)
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
Study: NCT03245229
Drug: Aprocitentan
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral administration
Study: NCT00630682
Drug: Dextroamphetamine
Normalized name: Dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 week placebo and 8 weeks 60mg d-AMP QD.
Study: NCT02869984
Drug: Ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT00745615
Drug: Laquinimod
Normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.
Study: NCT04582097
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: angiotensin-converting enzyme inhibitor